Not yet recruitingInterventionalPhase 4Last updated Aug 14, 2026

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes - DISCO Study

Overview

ClinicalTrials.gov ID: NCT07766109
Lead Sponsor: University Hospital, ToulouseOTHER
Brief Summary: SGLT-2 inhibitors are recommended treatments for managing heart failure patients. In cases of surgery, it is recommended to stop the treatment 3 days before surgery due to the risk of postoperative euglycemic diabetic ketoacidosis. However, several data suggest that it may be beneficial to maintain SGLT-2i treatment given the possibility of improving postoperative cardiovascular outcomes. Investigator team wish to conduct a randomized controlled trial to test the hypothesis that preoperative maintenance of SGLT-2i is superior to discontinuing them 3 days before surgery in improving postoperative cardiovascular outcomes.

Status

Study Record Dates

NCT04340908Unknown status

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

NCT05590143Active, not recruiting

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

NCT06326528Unknown status

SGLT2 Inhibitors and Perioperative Period

NCT06825156Completed

Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors

NCT05621551Completed

Dapagliflozin Therapy In Cardiac Surgery

NCT06432751Completed

Pre-operative Exposure to SGLT2 Inhibitors and Post-operative Acute Renal Failure in Cardiac Surgery